[The question and analysis about maintenance therapy in advanced non-small cell lung cancer].
Recently, several studies have been carried about maintenance therapy in non-small cell lung cancer, and some chemotherapy agents have been approved for clinical practice. But there are still a lot of questions about maintenance therapy that we have to consider. For example, the defects of design in maintenance therapy trials; how to choose gold standard of maintenance therapy for evaluation; who benefit from the maintenance therapy and how to estimate pharmaceutical economics. In this paper, we will make deep analysis about these issues.
Department of Lung Cancer, 307 Hospital of PLA, Beijing 100071, China.
Xiaoqing
X
Liu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology